AACR 2022 | The role of radiopharmaceuticals in the treatment landscape of prostate cancer

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medical College, New York, NY, reflects on the current clinical applications of radiopharmaceuticals in prostate cancer therapy and how these treatments may be used in the future. There are currently two approved radiopharmaceuticals, radium-223 and Lutetium-177 PSMA, which are regularly used in the treatment of prostate cancer. Both radiotherapies tend to be late-line and in combination with hormonal or steroidal therapies. Future research is needed to evaluate radiotherapies in formal combinations with more modern treatments and earlier in the disease state paradigm. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.